XML 42 R31.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

REVENUE (Tables) | 9 Months Ended
--- | ---
Jul. 31, 2024
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended July 31,
| 2024 |  | 2023
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 251 |  |  | $ | 170 |  |  | $ | 205 |  |  | $ | 626 |  |  | $ | 270 |  |  | $ | 159 |  |  | $ | 238 |  |  | $ | 667 |
Europe | 193 |  |  | 113 |  |  | 126 |  |  | 432 |  |  | 203 |  |  | 108 |  |  | 121 |  |  | 432 |
Asia Pacific | 338 |  |  | 128 |  |  | 54 |  |  | 520 |  |  | 381 |  |  | 129 |  |  | 63 |  |  | 573 |
Total | $ | 782 |  |  | $ | 411 |  |  | $ | 385 |  |  | $ | 1,578 |  |  | $ | 854 |  |  | $ | 396 |  |  | $ | 422 |  |  | $ | 1,672 |
| Nine Months Ended July 31,
| 2024 |  | 2023
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 735 |  |  | $ | 501 |  |  | $ | 657 |  |  | $ | 1,893 |  |  | $ | 819 |  |  | $ | 467 |  |  | $ | 744 |  |  | $ | 2,030 |
Europe | 605 |  |  | 335 |  |  | 376 |  |  | 1,316 |  |  | 649 |  |  | 309 |  |  | 363 |  |  | 1,321 |
Asia Pacific | 1,042 |  |  | 382 |  |  | 176 |  |  | 1,600 |  |  | 1,203 |  |  | 388 |  |  | 203 |  |  | 1,794 |
Total | $ | 2,382 |  |  | $ | 1,218 |  |  | $ | 1,209 |  |  | $ | 4,809 |  |  | $ | 2,671 |  |  | $ | 1,164 |  |  | $ | 1,310 |  |  | $ | 5,145 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Nine Months Ended
| July 31, |  | July 31,
| 2024 |  | 2023 |  | 2024 |  | 2023
| (in millions)
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical | $ | 540 |  |  | $ | 592 |  |  | $ | 1,647 |  |  | $ | 1,843 |
Chemicals and Advanced Materials | 356 |  |  | 378 |  |  | 1,110 |  |  | 1,162 |
Diagnostics and Clinical | 242 |  |  | 241 |  |  | 709 |  |  | 730 |
Food | 144 |  |  | 151 |  |  | 440 |  |  | 472 |
Academia and Government | 128 |  |  | 146 |  |  | 417 |  |  | 451 |
Environmental and Forensics | 168 |  |  | 164 |  |  | 486 |  |  | 487 |
Total | $ | 1,578 |  |  | $ | 1,672 |  |  | $ | 4,809 |  |  | $ | 5,145 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 556 |  |  | $ | 643 |  |  | $ | 1,734 |  |  | $ | 2,091 |
Non-instrumentation and other | 1,022 |  |  | 1,029 |  |  | 3,075 |  |  | 3,054 |
Total | $ | 1,578 |  |  | $ | 1,672 |  |  | $ | 4,809 |  |  | $ | 5,145 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the nine months ended July 31, 2024:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2023 |  | $ | 616 |
Net revenue deferred in the period |  | 456 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (422) |
Change in deferrals from customer cash advances, net of revenue recognized |  | (8) |
Currency translation and other adjustments |  | 4 |
Ending balance as of July 31, 2024 |  | $ | 646 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration